EUVIMEDEUVIMED entdecken
Open Access

Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients

J Bryan Iorgulescu iD, Timothy Blewett, Kan Xiong iD, Andjela Crnjac iD, Ruolin Liu, Sainetra Sridhar, David A Braun, MacLean C Sellars, Ju Cheng, Justin Rhoades, David A Reardon, G Mike Makrigiorgos iD und 2 weitere

Clinical Chemistry · 2025

DOI: 10.1093/clinchem/hvae178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2025. Verfasst von J Bryan Iorgulescu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Hauptthemen laut MEDLINE: Glioblastoma, Circulating Tumor DNA, Cell-Free Nucleic Acids, Brain Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients. Transiently attenuating cfDNA clearance from the body—thereby, allowing more cfDNA to be sampled—has been proposed to improve the performance of liquid biopsy diagnostics. However, there is a paucity of clinical data on the effect of higher cfDNA recovery. Here, we investigated the impact of collecting greater quantities of cfDNA on circulating tumor DNA (ctDNA) sensitivity in the “low-shedding” cancer type glioblastoma by analyzing up to approximately 15-fold more plasma than routinely obtained clinically.

Methods

We tested 70 plasma samples (median 17.0 mL, range 2.5–66.5) from 8 IDH-wild-type glioblastoma patients using an optimized version of the MAESTRO-Pool ctDNA assay. Results were compared with simulated single-blood-tube equivalents of cfDNA. ctDNA results were then compared with magnetic resonance imaging (MRI) and pathology assessments of true progression vs pseudoprogression in glioblastoma patients.

Results

Larger cfDNA yields exhibited a doubling in ctDNA-positivity while achieving a median specificity of 99% and more precise ctDNA quantification. In 8 glioblastoma patients, ctDNA was detected in 88%, including at multiple timepoints in 6/7. In the setting of indeterminate progression by MRI, our data suggested that MAESTRO-Pool with large plasma volumes can help distinguish true glioblastoma progression from pseudoprogression.

Conclusions

Our findings provide a proof-of-principle that most glioblastomas shed ctDNA into plasma and that greater ctDNA yields could help improve liquid biopsies for “low-shedding” cancer types such as glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCirculating Tumor DNACell-Free Nucleic AcidsBrain NeoplasmsHumansLiquid BiopsyMiddle AgedFemaleAgedMaleAdultBiomarkers, TumorMagnetic Resonance Imaging

Substanzen

Circulating Tumor DNACell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • Broad Institute of MIT and Harvard, Cambridge, MA, United States.
  • Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

ORCID-Profile: J Bryan Iorgulescu, Kan Xiong, Andjela Crnjac, G Mike Makrigiorgos

Förderung

  • NCI NIH HHS

Zitieren

APA

Iorgulescu, J. B., Blewett, T., Xiong, K., Crnjac, A., Liu, R., Sridhar, S., Braun, D. A., Sellars, M. C., Cheng, J., Rhoades, J., Reardon, D. A., Makrigiorgos, G. M., Wu, C. J., & Adalsteinsson, V. A. (2025). Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae178

Vancouver

Iorgulescu JB, Blewett T, Xiong K, Crnjac A, Liu R, Sridhar S, et al. Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvae178

BibTeX
@article{Iorgulescu2025,
  author = {Iorgulescu, J Bryan and Blewett, Timothy and Xiong, Kan and Crnjac, Andjela and Liu, Ruolin and Sridhar, Sainetra and Braun, David A and Sellars, MacLean C and Cheng, Ju and Rhoades, Justin and Reardon, David A and Makrigiorgos, G Mike and Wu, Catherine J and Adalsteinsson, Viktor A},
  title = {Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients},
  journal = {Clinical Chemistry},
  year = {2025},
  doi = {10.1093/clinchem/hvae178}
}
Kostenlos starten →